{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:23Z","timestamp":1794047423386,"version":"4.8.0"},"reference-count":15,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2022.282237","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T03:23:51Z","timestamp":1674098631000},"page":"2224-2228","source":"Crossref","is-referenced-by-count":1,"title":["Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia"],"prefix":"10.3324","volume":"108","author":[{"given":"Josephine A.","family":"Adattini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette S.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole Wong","family":"Doo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"McLachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"50768","doi-asserted-by":"crossref","unstructured":"Cortes JE, Saglio G, Kantarjian HM. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016; 34(20):2333-2340.","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"50769","doi-asserted-by":"crossref","unstructured":"Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing. Blood Rev. 2018; 32(4):289-299.","DOI":"10.1016\/j.blre.2018.01.004"},{"key":"50770","doi-asserted-by":"crossref","unstructured":"Deininger MW, Shah NP, Altman JK. Chronic myeloid leukemia, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020; 18(10):1385-1415.","DOI":"10.6004\/jnccn.2020.0047"},{"key":"50771","unstructured":"National Cancer Institute (U.S.). Common Terminology Criteria for Adverse Events (CTCAE) v5.0: U.S. Department of Health and Human Services. 2017. Publisher Full Text|"},{"key":"50772","doi-asserted-by":"crossref","unstructured":"Naranjo CA, Busto U, Sellers EM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-245.","DOI":"10.1038\/clpt.1981.154"},{"key":"50773","unstructured":"R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. 2020."},{"key":"50774","doi-asserted-by":"crossref","unstructured":"Adattini JA, Gross AS, Wong Doo N, McLachlan AJ. Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukaemia: an Australian experience. Pharmacol Res Perspect. 2022; 10(5):e01005.","DOI":"10.1002\/prp2.1005"},{"key":"50775","doi-asserted-by":"crossref","unstructured":"Marin D, Hedgley C, Clark RE. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood. 2012; 120(2):291-294.","DOI":"10.1182\/blood-2012-01-407486"},{"key":"50776","doi-asserted-by":"crossref","unstructured":"Cortes JE, Jiang Q, Wang J. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study. Leukemia. 2020; 34(8):2064-2073.","DOI":"10.1038\/s41375-020-0805-1"},{"key":"50777","doi-asserted-by":"crossref","unstructured":"Jabbour E, Kantarjian HM, Saglio G. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014; 123(4):494-500.","DOI":"10.1182\/blood-2013-06-511592"},{"key":"50778","doi-asserted-by":"crossref","unstructured":"Shah NP, Kim DW, Kantarjian H. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010; 95(2):232-240.","DOI":"10.3324\/haematol.2009.011452"},{"key":"50779","doi-asserted-by":"crossref","unstructured":"Chuah CT, Nakamae H, Shen ZX, Bradley-Garelik MB, Kim DW. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase. Leuk Lymphoma. 2014; 55(9):2093-2100.","DOI":"10.3109\/10428194.2013.866663"},{"key":"50780","doi-asserted-by":"crossref","unstructured":"Fox LC, Cummins KD, Costello B. The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. Blood Adv. 2017; 1(13):802-811.","DOI":"10.1182\/bloodadvances.2016003889"},{"key":"50781","doi-asserted-by":"crossref","unstructured":"Nightingale G, Skonecki E, Boparai MK. The impact of polypharmacy on patient outcomes in older adults with cancer. Cancer J. 2017; 23(4):211-218.","DOI":"10.1097\/00130404-201707000-00004"},{"key":"50782","unstructured":"Australian Institute of Health and Welfare. Cancer data in Australia. Canberra: Australian Institute of Health and Welfare. 2020."}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282237\/75897","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.282237\/75898","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10941\/75214","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:13Z","timestamp":1794045793000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.282237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.282237","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,19]]}}}